Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol concentration in male, but not in female patients with familial hypercholesterolemia

Atherosclerosis

Volumn 146, Issue 1, 1999, Pages 167-174

  Hoogerbrugge, Nicoline ^a   Jansen, Hans ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Atorvastatin; Cholesterol; Gender; Hepatic lipase; LDL size; Lipoprotein lipase

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; CARDIOVASCULAR RISK; DRUG EFFECT; ENZYME ACTIVITY; FAMILIAL HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIPID METABOLISM; PARTICLE SIZE; PRIORITY JOURNAL;

ADULT; ANALYSIS OF VARIANCE; ANTICHOLESTEREMIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PYRROLES; SEX DISTRIBUTION; TREATMENT OUTCOME;

EID: 0032772992     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00125-2     Document Type: Article

References (36)

1. Bakker-Arkema RG, Best J, Fayyad R, et al. A brief paper of the efficacy and safety of atorvastatin in early clinical trials. Atherosclerosis 1997;131:17-23.
2. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. J Am Med Assoc 1996;275:128-33.
3. Black DM. Atrovastatin: a step ahead for HMG-CoA reductase inhibitors. Atherosclerosis 1995;129:307-10.
4. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscl Thromb Vase Biol 1995;15:678-82.
5. Bocan TM, Ferguson E, McNaklly W, et al. Hepatic and non-hepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor-(II-98): comparison with selected HMG-CoA reductase inhibitors. Biochemn Biophys Acta 1992;1123:133-44.
6. Ness GC, Chambers CM, Lopez D. Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity. J Lipid Res 1998;39:75-84.
7. Havel RJ, Ede HA, Bragdon JH. Distribution and composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345-53.
8. Lingren FT, Jensen LC, Wills RD, Freeman NK. Flotation rates, molecular weights and hydrated densities of lower density lipoproteins. Lipids 1969;4:327-34.
9. Lamarche B, Tcherno A, Moorjani S, et al. Small, dense low-density lipoprotein particles as predictor of the ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation 1997;94:69-75.
10. Austin MA, Breslow JL, Hennekens CH, et al. Low density lipoprotein subclass patterns and risk of myocardial infarction. J Am Med Assoc 1988;260:1917-21.
11. Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic phenotype, pattern-B. Am J Med 1993;94:350-6.
12. de Graaf J, Hendriks JCM, Demacker PNM, Stalenhoef AFH. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscl Thromb Vase Biol 1991;11:298-306.
13. Campos H, Arnold KS, Balestra ME, Innerarity TL, Krauss RM. Differences in receptor binding of LDL subfractions. Arterioscl Thromb Vase Biol 1996;16:794-801.
14. Griffin BA, Packard CJ. Metabolism of VLDL and LDL sub-classes. Curr Opin Lipid 1994;5:2006.
15. Jansen H, Hop W, van Tol A, Bruschke AV, Birkenhager JC. Hepatic lipase and lipoprotein lipase are not major determinants of the low density lipoprotein subclass pattern in human subjects with coronary heart disease. Atherosclerosis 1994;107:45-54.
16. Auwerx JH, Marzetta CA, Hokanson JE, Brunzell JD. Large buoyant LDL-like particles in hepatic lipase deficiency. Arteriosclerosis 1989;9:319-25.
17. Zambon A, Austin MA, Brown BG, Hokanson JE, Brunzell JD. Effect of hepatic lipase on LDL in normal men and those with coronary disease. Arterioscl Thromb Vase Biol 1993;13:147-53.
18. Campos H, Dreon DM, Krauss RM. Associations of hepatic and lipoprotein lipase activities with changes in dietary composition and low density lipoprotein subclasses. J Lipid Res 1995;36:462-72.
19. Jones P, Kafonek S, Laurora I, Pharm D, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholestrerolemia (the curves study). Am J Cardiol 1998;81:582-7.
20. Colvin PL, Auerbach BJ, Case LD, Hazzard WR, Applebaum-Bowden D. A dose-response relationship between sex hormone induced change in hepatic lipase triglyceride lipase and high-density lipoprotein cholesterol in postmenopausal women. Metab Clin Exp 1991;40:1052-6.
21. 2+/dextran sulfate in its enzymatic measurement. Clin Chem 1978;24:931-3.
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of preparative ultracentrifugation. Clin Chem 1972;18:499-502.
23. Jansen H, Ghanem H, Kuypers JHSAM, Birkenhäger JC. Autoantibodies against malondialdehyde-modified LDL are elevated in subjects with an LDL subclass pattern B. Atherosclerosis 1995;115:25-262.
24. Austin MA, Krauss RM. Genetic control of low-density lipoprotein subclasses. Lancet 1986;2:592-5.
25. McNamara JR, Jenner JL, Zhengling L, Wilson PWF, Schaefer EJ. Change in LDL particle size is associated with change in plasma triglyceride concentration. Arterioscl Thromb Vasc Biol 1992;12:1284-90.
26. Dugi KA, Feuerstein IM, Hill S, et al. Lipoprotein lipase correlates positively and hepatic lipase inversely with calcific atherosclerosis in homozygous familial hypercholesterolemia. Arterioscler Thromb Vase Biol 1997;17:354-64.
27. Jansen H, Hulsmann WC, Heparin-releasable (liver) lipase(s) may play a role in the uptake of cholesterol by steroid-secreting tissues. Trends Biochem Sci 1980:265-269.
28. Jansen H, van Toi A, Hulsmann WC. On the metabolic function of heparin releasable liver lipase. Biochem Biophys Res Commun 1980;92:53-9.
29. Nislon-Ehle P, Garfunkel AS, Schotz MC. Lipolytic enzymes and plasma lipoprotein metabolism. Annu Rev Biochem 1980;49:668-93.
30. Cabezas MC, de Bruin TWA, Kock LAW, et al. Simvastatin improves chylomicron remnant removal in familial combined hyperlipidemia without changing chylomicron conversion. Metabolism 1993;42:497-503.
31. Kagami A, Ishikawa T, Tada N, et al. Effects of probucol and pravastatin on plasma lipids, activities on postheparin lipoprotein lipase, and lecithin cholesterol acyltransferase and apo A-1 containing lipoproteins with and without apo AII in patients with moderate hypercholesterolemia. Clin Biochem 1993;26:101-7.
32. Tan CE, Caslake MJ, Bedford D, et al. Relation between plasma lipids upases and VLDL and LDL subfraction patterns in normolipidemic men and women. Arterioscler Thromb Vasc Biol 1995;15:1839-48.
33. Breckenridge WC, Little JA, Alaupovic P, et al. Lipoprotein abnormalities associated with familial deficiency of hepatic lipase. Atherosclerosis 1982;45:161-79.
34. Connelly PW, Maguire GF, Lee M, Little JA. Plasma lipoproteins in familial hepatic lipase deficiency. Arteriosclerosis 1990;10:40-8.
35. Auwerx JH, Babirak SP, Hokanson JE, et al. Coexistence of abnormalities of hepatic lipase and lipoprotein lipase in a large family. Am J Hum Genet 1990;46:470-7.
36. Busch SJ, Barnhart RL, Martin GA, et al. Human hepatic triglyceride lipase expression reduces high-density lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice. J Biol Chem 1994;269:16376-82.